TrademarkDir
ANTIBODIES BY DESIGN
LIVE

Serial Number

88049386

Owner

XENCOR, INC.

Attorney

Gabrielle A. Holley

First Use Date

Mar 24, 2021

Filing Date

Jul 23, 2018

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

ANTIBODIES BY DESIGN Trademark

Serial Number: 88049386 • Registration: 6866551

ANTIBODIES BY DESIGN is a trademark filed by XENCOR, INC. on July 23, 2018. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

XENCOR, INC. (30 trademarks)

111 WEST LEMON AVENUE
MONROVIA, CA 91016

Entity Type: 03

Trademark Details

Filing Date

July 23, 2018

Registration Date

October 4, 2022

First Use Anywhere

March 24, 2021

First Use in Commerce

March 24, 2021

Published for Opposition

July 2, 2019

Filing History

APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Mar 17, 2023 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Mar 17, 2023 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Mar 17, 2023 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Mar 17, 2023 REAP
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Mar 17, 2023 COAR
NOTICE OF REGISTRATION CONFIRMATION EMAILED
Oct 4, 2022 NRCC
REGISTERED-PRINCIPAL REGISTER
Oct 4, 2022 R.PR
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Sep 2, 2022 SUNA
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Sep 1, 2022 CNPR
STATEMENT OF USE PROCESSING COMPLETE
Aug 8, 2022 SUPC
USE AMENDMENT FILED
Aug 2, 2022 IUAF
TEAS STATEMENT OF USE RECEIVED
Aug 2, 2022 EISU
ASSIGNED TO EXAMINER
Apr 8, 2022 DOCK
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 23, 2022 EXRA
SOU EXTENSION 5 GRANTED
Feb 22, 2022 EX5G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Feb 22, 2022 AITU
SOU EXTENSION 5 FILED
Feb 15, 2022 EXT5
SOU TEAS EXTENSION RECEIVED
Feb 15, 2022 EEXT
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Nov 2, 2021 CHAN
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 2, 2021 TCCA
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Nov 2, 2021 COAR
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Nov 1, 2021 TCCA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Nov 1, 2021 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Nov 1, 2021 REAP
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 26, 2021 EXRA
SOU EXTENSION 4 GRANTED
Aug 24, 2021 EX4G
SOU EXTENSION 4 FILED
Aug 24, 2021 EXT4
SOU TEAS EXTENSION RECEIVED
Aug 24, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 25, 2021 EXRA
SOU EXTENSION 3 GRANTED
Feb 23, 2021 EX3G
SOU EXTENSION 3 FILED
Feb 23, 2021 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 23, 2021 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 18, 2020 EXRA
SOU EXTENSION 2 GRANTED
Aug 14, 2020 EX2G
SOU EXTENSION 2 FILED
Aug 14, 2020 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 14, 2020 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jan 31, 2020 EXRA
SOU EXTENSION 1 GRANTED
Jan 29, 2020 EX1G
SOU EXTENSION 1 FILED
Jan 29, 2020 EXT1
SOU TEAS EXTENSION RECEIVED
Jan 29, 2020 EEXT
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 13, 2020 ARAA
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 13, 2020 REAP
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 27, 2019 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 2, 2019 NPUB
PUBLISHED FOR OPPOSITION
Jul 2, 2019 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 12, 2019 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 23, 2019 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 22, 2019 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 22, 2019 CRFA
ASSIGNED TO LIE
May 21, 2019 ALIE
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 14, 2019 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Nov 14, 2018 GNRN
NON-FINAL ACTION E-MAILED
Nov 14, 2018 GNRT
NON-FINAL ACTION WRITTEN
Nov 14, 2018 CNRT
ASSIGNED TO EXAMINER
Nov 8, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 27, 2018 NWOS
NEW APPLICATION ENTERED
Jul 26, 2018 NWAP

Related Trademarks

More from this Owner

PROTEINS BY DESIGN

PROTEINS BY DESIGN

PROTEINS BY DESIGN

PROTEINS BY DESIGN

PROTEINS BY DESIGN

PROTEINS BY DESIGN

NEXMAB

NEXMAB

NEXMAB

NEXMAB

IMMUNOFILTER

IMMUNOFILTER